Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736207 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL10201899 | 0.93 | CYP3A4 (0.55) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL2736271 | 0.92 | CYP3A4 (0.54) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL13535190 | 0.91 | CYP3A4 (0.55) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL3362046 | 0.90 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL3361380 | 0.90 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL14638407 | 0.90 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL13535195 | 0.90 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL13535191 | 0.90 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL7180371 | 0.90 | CYP3A4 (0.51) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105753806-B | A kind of heterogeneous synthetic method of Ritonavir intermediate and its application | 厦门市蔚嘉化学科技有限公司 | 2018-06-05 | — | — | CN | claimed |
| CN-105753806-A | Heterogeneous synthetic method and application of Ritonavir intermediate | 厦门市蔚嘉化学科技有限公司 | 2016-07-13 | — | — | CN | claimed |
| EP-3112355-B1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES INC (US) | 2020-04-29 | — | — | EP | disclosed |
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| CN-105753806-B | A kind of heterogeneous synthetic method of Ritonavir intermediate and its application | 厦门市蔚嘉化学科技有限公司 | 2018-06-05 | — | — | CN | disclosed |
| US-9891239-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-05-25 | — | — | US | disclosed |
| US-9575080-B2 | — | — | 2017-02-21 | — | — | US | disclosed |
| CN-105753806-A | Heterogeneous synthetic method and application of Ritonavir intermediate | 厦门市蔚嘉化学科技有限公司 | 2016-07-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CYP3A4 415/4885CYP2D6 140/4885CYP2C19 716/4885 |
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CYP3A4 415/4885CYP2D6 140/4885CYP2C19 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.